Transgenic Overexpression of LARGE Induces α-Dystroglycan Hyperglycosylation in Skeletal and Cardiac Muscle by Brockington, Martin et al.
Transgenic Overexpression of LARGE Induces a-
Dystroglycan Hyperglycosylation in Skeletal and Cardiac
Muscle
Martin Brockington
1., Silvia Torelli
1., Paul S. Sharp
2, Ke Liu
2, Sebahattin Cirak
1, Susan C. Brown
3,
Dominic J. Wells
2,3, Francesco Muntoni
1*
1Dubowitz Neuromuscular Centre, University College London (UCL) Institute of Child Health and Great Ormond Street Hospital, London, United Kingdom, 2Department
of Cellular and Molecular Neuroscience, Imperial College, London, United Kingdom, 3Department of Veterinary Basic Science, Royal Veterinary College, London, United
Kingdom
Abstract
Background: LARGE is one of seven putative or demonstrated glycosyltransferase enzymes defective in a common group of
muscular dystrophies with reduced glycosylation of a-dystroglycan. Overexpression of LARGE induces hyperglycosylation of
a-dystroglycan in both wild type and in cells from dystroglycanopathy patients, irrespective of their primary gene defect,
restoring functional glycosylation. Viral delivery of LARGE to skeletal muscle in animal models of dystroglycanopathy has
identical effects in vivo, suggesting that the restoration of functional glycosylation could have therapeutic applications in
these disorders. Pharmacological strategies to upregulate Large expression are also being explored.
Methodology/Principal Findings: In order to asses the safety and efficacy of long term LARGE over-expression in vivo,w e
have generated four mouse lines expressing a human LARGE transgene. On observation, LARGE transgenic mice were
indistinguishable from the wild type littermates. Tissue analysis from young mice of all four lines showed a variable pattern
of transgene expression: highest in skeletal and cardiac muscles, and lower in brain, kidney and liver. Transgene expression
in striated muscles correlated with a-dystroglycan hyperglycosylation, as determined by immunoreactivity to antibody IIH6
and increased laminin binding on an overlay assay. Other components of the dystroglycan complex and extracellular matrix
ligands were normally expressed, and general muscle histology was indistinguishable from wild type controls. Further
detailed muscle physiological analysis demonstrated a loss of force in response to eccentric exercise in the older, but not in
the younger mice, suggesting this deficit developed over time. However this remained a subclinical feature as no pathology
was observed in older mice in any muscles including the diaphragm, which is sensitive to mechanical load-induced damage.
Conclusions/Significance: This work shows that potential therapies in the dystroglycanopathies based on LARGE
upregulation and a-dystroglycan hyperglycosylation in muscle should be safe.
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Introduction
The muscular dystrophies (MDs) are a clinically and genetically
heterogeneous group of conditions characterised by progressive
muscle degeneration [1]. Defects in a wide variety of proteins with
diversefunctionsinskeletalmuscleareknowntocausethesedisorders
[1]. In the last few years the most common group of MDs after
Duchenne muscular dystrophy has been shown to share the novel
pathological feature of a hypoglycosylated form of a-dystroglycan (a-
DG) [2,3]. To date, mutations in seven genes encoding putative or
demonstrated glycosyltransferases have been found to underlie these
disorders, collectively known as secondary dystroglycanopathies:
Protein-O-mannosyl transferase1 (POMT1; OMIM 607423) [4], Protein-O-
mannosyl transferase 2 (POMT2; OMIM 607439) [5], Protein-O-mannose
1,2-Nacetylglucosaminyltransferase1 (POMGnT1; OMIM 606822) [6],
Fukutin (OMIM 607440) [7], Fukutin-related protein (FKRP;O M I M
606596) [8,9], LARGE (OMIM 603590) [10] and Dol-P-Man
synthase subunit 3 (DPM3, OMIM 605951) [11]. The clinical
spectrum of dystroglycanopathies is uncommonly wide [3]. At the
severe end of the spectrum are conditions characterised by forms of
congenital muscular dystrophy (CMD) with severe structural brain
and variable eye defects: Walker-Warburg-Syndrome (WWS
[OMIM 236670]), Muscle-Eye-Brain disease (MEB [OMIM
253280]), Fukuyama CMD (FCMD [OMIM 253800]) and MDC1D
[OMIM 608840]) [3]. Less severe phenotypes include one form of
congenital muscular dystrophy, MDC1C [OMIM 606612] [9] and
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607155] [8], LGMD 2K [OMIM 609308] [12], LGMD 2M
[OMIM 611588] [13] and the variant due to DPM3 deficiency [11].
Brain involvement is either mild (LGMD2K) or absent (LGMD2I
and LGMD2M) in patients with the limb girdle phenotypes.
Although each variant was originally associated with mutations in a
particular gene, it is now clear that each of these genes can give rise to
a similar broad phenotypic spectrum and that the severity of the
condition is more dependent on the degree of perturbation of a-DG
glycosylation than the gene primarily mutated [14]. No effective
therapy for any of these progressive conditions exists [15].
Dystroglycan was originally identified as a component of the
dystrophin associated glycoprotein complex (DGC) present at the
sarcolemma of skeletal muscle [16], though it is now clear that it
has a much wider tissue distribution [17]. The DAG1 gene encodes
a precursor protein that is post-translationally cleaved into a and
bsubunits [18]. b-Dystroglycan (b-DG) is a 43kDa transmembrane
protein whereas a-DG is an extracellular peripheral membrane
protein non-covalently bound to the b subunit [16]. The full
function of the DGC is not completely known although it forms a
structural link between the extracellular matrix and the actin
associated cytoskeleton [19]. The mature a-DG protein has
globular N- and C-terminal domains separated by a central mucin
rich domain [16]. The N-terminal domain (aa 29 to aa 312)
appears to be cleaved by a convertase-like activity [20]. The
predicted molecular mass of a-DG is 74 kDa but its apparent
molecular weight ranges from 120 kDa (brain) to 156 kDa (skeletal
muscle), due to tissue specific and developmentally regulated
patterns of O-glycosylation within the mucin rich domain [16].
Structural information regarding the sugars decorating a-DG is
limited [21]. However one structure that has received attention is
the rare O-mannosyl linked oligosaccharide Neu5Ac (a2-3)Gal(b1-
4)GlcNAc(b1-2)Man-Ser/Thr [22]. A complex of POMT1 and
POMT2 is responsible for initiating its synthesis which is then
extended by the action of POMGnT1 [23]. It was originally
suggested that this mannosylated structure constituted a laminin
receptor, though more recent studies have showed that enzymatic
degradation of the terminal Neu5Ac actually results in increased
laminin binding, suggesting other unknown structures also mediate
this process [24].
Recently, using mass spectrometry and nuclear magnetic
resonance (NMR) –based structural analyses, the group of Kevin
Campbell identified a phosphorylated O-mannosyl glycan on
recombinant a-DG, which was required for laminin binding [25].
This phosphorylation occurs on the O-linked mannose of a-DG.
Further work from the Lance Wells’ laboratory demonstrated that
a-DG is mannosylated at 9 residues, while GalNAcylation occurs
at 14 sites [26].
LARGE is a putative glycosyltransferase mutated in the
myodystrophy mouse (LARGE-myd) [27] and in patients affected
by MDC1D [10], one of the dystroglycanopathy variants
associated with skeletal muscle and structural brain involvement.
Sequence analysis predicts LARGE to contain two catalytic
domains [28,29]. The first domain is related to bacterial a-
glycosyltransferases, while the second is most closely related to
human b-1,3-Nacetylglucosaminyltransferase, required for synthe-
sis of the poly-N-acetyllactosamine backbone (Galb1-4GlcNAcb1-
3)n found on N- and O-glycans [28]. Although neither of these
structures is present on a-DG [21], there is strong evidence that
LARGE plays a pivotal role in the functional glycosylation of a-
DG. Firstly, the N-terminal domain of a-DG interacts directly
with LARGE and this association is a requirement for physiolog-
ical glycosylation [20]. Secondly, the forced overexpression of
LARGE in mouse skeletal muscle, as well as cultured human and
mouse cell lines, results in increased expression of functionally
glycosylated a-DG (hyperglycosylation) and a corresponding
increase in its binding capacity for laminin and other ligands
[30,31]. Moreover, the overexpression of LARGE generates
highly glycosylated a-DG in cell lines derived from patients with
a dystroglycanopathy, irrespective of the underlying gene defect
[30]. While the precise nature of the LARGE induced glycosyl-
ation remains undetermined, it has been suggested that LARGE
requires mannosylated a-DG to exert its action [25]. Furthermore
LARGE gene transfer experiments achieved a-DG hyperglycosy-
lation in animal models of fukutin and PomGnt1 related muscular
dystrophies [32], thus LARGE overexpression can presumably
activate alternative pathways resulting in functional a-DG
glycosylation in these models. None of the other enzymes
responsible for dystroglycanopathies has a similar effect; however
we have previously demonstrated that the overexpression of the
LARGE paralog GYLTL1B (or LARGE2) is equally capable of
hyperglycosylating a-DG in cultured cells [29,31,33]; mutations in
this gene have not yet been associated with a human pathology.
The presence of alternative pathways of a-DG glycosylation
opens new avenues for the development of therapies in dystrogly-
canopathies [15,30,34,35]. Overexpression of LARGE (or
LARGE2) by means of genetic or pharmacological intervention
could restore ligand binding and improve muscle strength in
patients affected by dystroglycanopathies. However, prior to a
therapeutic strategy based on the over-expression of LARGE being
considered, an assessment of the safety of its long term over-
expression and its efficacy with respect to the hyperglycosylation of
a-DG needs to be established in vivo. To this end we report here the
generation of four lines of LARGE overexpressing transgenic mice.
We have characterised the effect of transgene expression on a-DG
glycosylation in skeletal and cardiac muscle and brain, tissues which
are affected in dystroglycanopathy patients, as well as other tissues
not involved in these disorders. We show that the overexpression of
LARGE results in a robust hyperglycosylation of a-DG in skeletal
and cardiac muscle without any observable deleterious morpholog-
ical effect. Detailed analysis of the contractile properties of tibialis
anterior muscles however showed a loss of force in response to
eccentric exercise in older mice. This was not accompanied by any
morphological changes suggesting a mild subclinical defect. a-DG
wasnothyperglycosylatedinbraindespitelowlevelsofexpressionof
the transgene, which suggests that higher levels of LARGE are
necessary to achieve hyperglycosylation in a tissue, in which high
levels of endogenous Large are present.
Results
The generation of LARGE overexpressing transgenic mice
In order to generate transgenic mice we cloned human LARGE
into the pCAGGS expression vector which contains a human
cytomegalovirus enhancer situated upstream of the chicken b-actin
promoter and a rabbit b-globin 39 flanking sequence including a
polyadenylation signal [36,37]. Since antibodies to human
LARGE are not routinely available, the LARGE cDNA derived
from total human brain RNA was initially cloned into the pcDNA
3.1/V5-His expression vector. This directs the synthesis of a fusion
protein with the V5 epitope at the C terminal end. The DNA
sequence coding for this fusion product was subsequently
subcloned into pCAGGS (Figure 1). The transgene expression
vector harbouring the LARGE/V5 fusion sequence was digested
to release a 4kb cassette for micro injection. Founders were
identified by PCR from ear biopsies and were used to establish
independent transgenic lines by breeding to wild-type F1 hybrid
(C57BL106CBA/Ca) mice. Successful transmission of the trans-
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Expression of the transgene was confirmed by western blot
analysis and immunocytochemistry using a V5 antibody. In total
we identified seven transgenic founders, four of which transmitted
and expressed the transgene (lines 68, 76, 116, 126), one died
shortly after birth and the remaining two failed to transmit. The
four transgenic lines showed similar expression of the transgene
and a-DG hyperglycosylation (Fig 1B). Immunohistochemical
analysis was also comparable between all four expressing
transgenic lines.
LARGE transgenic mice are phenotypically
indistinguishable from their non transgenic litter mates
LARGE transgenic mice from each of the transmitting lines
showed no detectable differences in mortality, behaviour, mobility
and rate of weight gain compared to their non-transgenic
littermates under standard husbandry conditions. Breeding
performance was typical of the C57BL106CBA/Ca hybrid with
normal litter sizes and survival to weaning.
LARGE transgene expression in skeletal muscle resulted
in a-DG hyperglycosylation but had no effect on muscle
morphology
Histological analysis of each of the lines using haematoxylin and
eosin (H&E) staining showed no overall changes in muscle
morphology in either the quadriceps, soleus, tibialis anterior or extensor
digitorum longus of transgenic compared to aged matched non
transgenic litter mates (aged 2–4 months). Centrally located nuclei,
tissue fibrosis, necrosis and fatty infiltration, typical features of
dystrophy, were never observed (Figure 2A–B). Skeletal muscle
from transgenic and non transgenic mice was similar in terms of
fibre type composition as judged by NADH histochemical staining
(Figure 2C–D). LARGE transgene expression, detected using an
antibody to the V5 epitope, showed staining in only a proportion
of fibres in transverse section (Figure 2G). The analysis of
longitudinal sections confirmed that only discrete areas of each
fibre were V5 positive (Figure 2H) and this accounted for the
apparent lack of staining of several muscle fibres in transverse
sections. Immunostaining of transgenic skeletal muscle sections
with antibody IIH6 (kind gift from Dr KP Campbell), which
recognises a laminin binding site on a-DG [37,38] showed a
marked increase in immunolabelling in all muscle fibres of each of
the transgenic lines (Figure 2I–J). No difference between muscle
groups or between slow and fast fibres was observed (data not
shown). Immunostaining with antibodies to b-DG (Figure 2M–N)
and laminin-a2 (Figure 2O–P) was identical to non transgenic
litter mates. Western blotting of protein lysates from quadriceps
muscle demonstrated an increase in IIH6 immunoreactivity,
appearing as a broad smear on nitrocellulose membranes that
encompassed both wild type a-DG glycosylation and significantly
higher molecular weight products (Fig 3A). A laminin overlay
assay showed a corresponding increase in its binding capacity
relative to wild type dystroglycan (Figure 3A). The expression of b-
DG on western blot was unaltered (Figure 3A). Limb muscle
morphology was also studied in older transgenic mice (8 months)
from three different lines; no difference from aged control
littermates was found (Fig 2E–F). Immunostaining with IIH6
(Fig 2K–L) showed that hyperglycosylated a-DG was still
expressed in the old LARGE transgenic mice. Real-time qPCR
in these older transgenic mice showed persistent expression of the
transgene at levels similar to those in young mice (data not shown).
The morphology of neuromuscular junctions in one transgenic line
was also investigated in detail since dystroglycan and its
glycosylation play a central role in the development/maintenance
of these structures [39]. Using fluorescently tagged a-bungarotoxin
we visualised both the general organisation of the acetylcholine
receptors (AChRs) and the area of the postsynaptic membrane in
the diaphragm. These analyses failed to detect any gross
differences between transgenic and non transgenic mice (data
not shown). In addition, we compared the expression of two
unique glycoforms of a-DG restricted to the NMJ that are
recognised by the two cytotoxic T antigens (CT1 and CT2;
antibodies kindly provided by Dr PT Martin) to see if they were
altered in the presence of hyperglycosylation [40]. We could
observe no differences between transgenic and non transgenic
mice in the expression of these NMJ antigens (data not shown).
LARGE transgene expression in skeletal muscle does not
affect force generation but increases the susceptibility to
contraction-induced injury
We next examined whether overexpression of LARGE in
transgenic mice would have an impact on skeletal muscle function.
In order to achieve this, we measured in vivo, the isometric force
contractions of tibialis anterior (TA) muscles from LARGE
transgenic and the wild-type littermates at 2 and 8 months of
age. At both ages we observed no significant differences in the
weights, maximum absolute forces and specific forces of TA
muscles from LARGE transgenics compared to wild-type controls
(Fig. 4). We also tested the possibility that LARGE overexpression
may alter the resistance of TA muscles to contraction-induced
Figure 1. Generation of LARGE transgenic mouse. A. A schematic
representation of the LARGE expression cassette. The full-length V5
tagged LARGE cDNA was subcloned into the pCAGGS expression
vector. This vector consists of a synthetic CMVenhancer/and chicken b-
actin promoter sequence located upstream of the transgene and the
rabbit b-globin poly(A) sequence located downstream. Arrows repre-
sent position and orientation of PCR primers used to screen ear
biopsies. B. Western blotting analysis of protein lysates from wild type
and muscle tissues (quadriceps) from all the four LARGE transgenic lines
(68,76,116 and 126) using antibodies to a-DG IIH6, b-DG, and V5.
doi:10.1371/journal.pone.0014434.g001
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subjected to a series of lengthening contractions (15% of Lo,
Fig. 5A), which imposes additional stress on the sarcolemmal
membrane of muscle fibres. The impact of these repeated
lengthening contractions on force generation was measured over
time. We observed no significant difference in resistance to
contraction-induced injury in 2 month old LARGE transgenic
mice compared to control mice (Fig. 5B) However, at 8 months of
Figure 2. Immunocytochemistry of LARGE transgenic mouse
skeletal muscle. Serial transverse frozen sections (except longitudinal
section H) of quadriceps skeletal muscle from normal (A,C,I,M and O)
and transgenic LARGE mouse line 68 (B,D,G,H,J,N and P) aged 2 months.
E and K from control and F and L from transgenic LARGE mouse (line
68) aged 8 months. A,B,E and F: Haematoxylin and Eosin staining. C and
D: NADH staining. Immunolabeling of V5 tagged LARGE in transverse
(G) and longitudinal (H) section. V5 immunolabelling was only seen in
few fibres in transverse section whereas in the longitudinal section all
fibres appeared to be labelled. I–L immunolabelling of a-DG (IIH6). All
the fibres in the LARGE transgenic muscle (J and L) showed a stronger
staining compared to the control littermates (Iand K). No difference was
seen in the level of b-DG (M and N) and laminin a2 (O and P) in LARGE
transgenic muscle relative to the control. (Scale bar 50 mm).
doi:10.1371/journal.pone.0014434.g002
Figure 3. Western blot and laminin assay analysis of LARGE
transgenic mouse tissues. Western blot analysis of protein lysates
from wild type and LARGE transgenic (line 68) tissues using antibodies
to a-DG IIH6, b-DG, and V5. A. Wild type and LARGE transgenic
quadriceps muscle. When the membrane was exposed for a short period
using antibody IIH6 a clear band of higher molecular weight was
detected in the samples from LARGE transgenic muscle compared to
controls, while a longer exposure resulted in a continuous smear.
Laminin-1 overlay showed that hyperglycosylated a-DG has increased
laminin binding. b-DG expression was unaltered in transgenic mice.
B. Wild type and LARGE transgenic mouse cardiac muscle. Laminin-1
overlay showed that hyperglycosylated a-DG bound laminin with a
similar capacity to normally glycosylated dystroglycan. C. Wild type and
and LARGE transgenic total brain lysates. No hyperglycosylated a-DG
was seen using IIH6 in the LARGE transgenic brain samples even though
the LARGE transgene (V5) was clearly expressed. D. Western blot
analysis of protein lysates from control (1,3 and 5) and LARGE
transgenic (2,4,and 6) mice derived from: small intestine (1,2), liver
(3,4) and kidney (5,6). No hyperglycosylated a-DG was seen in any of
these tissues. Expression of V5 (LARGE) was only detectable in heavily
overexposed blots (data not shown). a-DG expression was unaltered in
all tissue samples.
doi:10.1371/journal.pone.0014434.g003
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to contraction-induced injury, as demonstrated by a 30% greater
decline in force generation compared to controls following 8
successive lengthening contractions (Fig. 5C). Even though there
continued to be no weight or phenotypic differences between the
transgenic and non-transgenic littermates prior to the assessment
of muscle physiology at 8 months of age, we examined diaphragms
from 9 month old transgenic mice as this muscle undergoes
repeated eccentric exercise but did not observe any signs of
pathology (data not shown).
LARGE transgene expression in cardiac muscle was not
uniform and correlated with a variable pattern of a-DG
hyperglycosylation
Histological analysis using haematoxylin and eosin staining of
sections of cardiac muscle from 2–4 month old transgenic mice
from each the four lines showed no differences compared to aged
matched non transgenic littermate controls (Figure 6A–B).
Immunohistochemical staining of cardiac muscle sections with a
V5 antibody showed a regional and patchy distribution of LARGE
transgene expression (Figure 6D). Approximately 25% of cardio-
myocytes had V5 expression and these were often but not
invariably grouped with a transmural distribution (Figure 6E).
There was a good correlation between cardiomyocytes showing a-
DG hyperglycosylation and transgene expression (Figure 6E–F
and 6D–H). Immunostaining with antibodies to b-DG (Figure 6I–
J) and laminin-a2 (Figure 6K–L) showed no differences from non
transgenic litter mates. Western blotting of cardiac muscle protein
lysates from transgenic mice using the a-DG antibody IIH6
showed the presence of two distinct bands (Figure 3B). The lower
band, which was equivalent to that seen in non transgenic litter
mates, presumably represents the form of a-dystroglycan in
cardiomyocytes not expressing the transgene, while the upper
band likely represents hyperglycosylated a-DG produced by
cardiomyocytes expressing the transgene. An overlay assay showed
that both species of a-DG bound laminin-1 with equal efficiency
(Figure 3B). The expression of b-DG was unaltered and V5
expression was only seen in the transgenic tissues (Figure 3D).
LARGE transgene expression in brain was variable and
did not induce a-DG hyperglycosylation
Immunohistochemical analysis of transgenic mouse brains from
all four lines showed regional expression of the LARGE transgene
as detected by V5 staining, including the hippocampus (Figure 7A–
C), cerebellum (Figure 7G–I) and cortex (Figure 7J–L), though
even within these areas expression was variable. Transgene
expression, as judged by double staining with the neuronal
markers NeuN and Ctip2, appeared to be largely restricted to
neurons (data not shown). In the cerebellum, expression was
further largely restricted to Purkinje cells (Figure 7G). We could
not detect a clear increase in the levels of IIH6 immunoreactivity
in cells expressing the transgene (Figure 7G–I) compared to
control (Figure 7D–F). A double staining using an antibody against
a marker for the Golgi apparatus (GM130) and V5 showed a clear
co-localisation in neuronal cells, demonstrating that the LARGE
transgene was properly localised in these cells (Figure 7J–L).
Western blotting of transgenic brain lysates using the antibody
IIH6 failed to identify a-DG hyperglycosylation in brain tissue
(Figure 3C).
The LARGE transgene was expressed at low levels in
kidney, liver and small intestine but did not induce a-DG
hyperglycosylation
We also investigated LARGE transgene expression in tissues not
implicated in the patho-physiology of the dystroglycanopathies.
These were kidney, liver and smooth muscle (small intestine).
Western blot analysis using the V5 antibody could only detect very
low levels of transgene expression on overexposed gels (data not
shown); a-DG was not hyperglycosylated in any of these tissues in
any of the transgenic lines (Figure 3D).
Real time qPCR analysis of LARGE transgenic tissues
In order to obtain further information on the levels of LARGE
involved in inducing a-DG hyperglycosylation we used real time
qPCR and TaqMan gene expression assays to quantify both the
levels of endogenous Large and LARGE transgene expression. In
wild type mice the expression of endogenous Large was found to
be on average 15–20 fold higher in the brain and 2 fold higher in
the heart relative to skeletal muscle (quadriceps) (Figure 8A). Skeletal
muscle from transgenic mice had identical patterns of endogenous
Large expression and therefore the presence of the LARGE
transgene appeared not to affect levels of endogenous Large.
Expression of the LARGE transgene in skeletal muscle was on
average 10–15 fold that of brain and around 4 fold higher than
heart (Figure 8B). Transgene expression in smooth muscle (small
intestine), kidney and liver was at levels lower than brain. Probes to
dystroglycan showed no differences in levels of expression of this
gene (data not shown).
LARGE hyperglycosylation does not affect the expression
of other genes involved in a-DG glycosylation
Finally, we used real time PCR in transgenic quadriceps muscle of
two month old mice (line 68) to investigate if LARGE transgene
expression altered the expression of other known genes involved in
dystroglycan glycosylation. These were Pomt1, Pomt2, Pomgnt1,
Fukutin, Fkrp and the Large paralog Large2 (Gyltl1b). No significant
difference in the levels of expression of any of these genes was seen
between aged matched transgenic and non transgenic littermates
(data not shown).
Discussion
Patients and animal models affected by dystroglycanopathies
have a deficiency in functionally glycosylated a-DG [2,34]. While
the precise glycosylation pattern of a-DG is currently not known
[21], several lines of evidence suggest that it is heterogeneous. a-
DG is one of the few mammalian proteins known to contain O-
mannosylated glycans [41] and now the sites which undergo this
modification have been clearly mapped [26]. Three of the protein
defects responsible for the dystroglycanopathies clearly participate
Figure 4. Isometric force contractions measurement in LARGE transgenic and the wild-type mouse muscle. Maximum isometric forces
of tibialis anterior (TA) muscles from 2 and 8 month old LARGE transgenic mice (LV5, line 126) and their age-matched wild-type littermates (WT) were
recorded in vivo and weighed following physiological assessments. (A) The weights of TA muscles from 2 month (2 mo) and 8 month (8 mo) old
LARGE trangenics (LV5) were not significantly different from the TA muscles of the age-matched wild-type controls. (B and C) Both the maximum
absolute forces (B) and the specific forces (C) of TA muscles from LARGE transgenics (LV5) at both 2 and 8 months of age were not significantly
different from their age-matched wild-type controls. Number of animals examined: 2 months, LV5 n=6; WT n=4; 8 months, LV5 n=4, WT n=4. All
values presented are mean and standard error of the mean (S.E.M).
doi:10.1371/journal.pone.0014434.g004
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PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e14434Figure 5. In situ Muscle Function and Lengthening Contraction. (A) Schematic representation of the lengthening contraction protocol,
designed to assess the muscles resistance to contraction-induced injury. TA muscles from both LARGE transgenics (line 126) and wild-type controls
were subjected to series of lengthening contractions and the effect on force generation was measured. (B) In two month old mice there was a
significant effect of the number of eccentric contractions on force drop, however, there was no significant difference between LARGE transgenic mice
a-DG in Transgenic LARGE Mice
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complex that confers full O-mannosyltransferase activity and
POMGnT1 catalyzes the transfer of N-acetylglucosamine to O-
mannosyl groups [23]. Regarding DPM3 deficiency, reduced
dolichol-phosphate-mannose (Dol-P-Man) synthase activity has
been associated with reduced O-mannosylation of a-DG [11].
The functions of the remaining 3 genes (Fukutin, FKRP and
LARGE) remain elusive. The LARGE protein is unusual in that it
is predicted to contain two putative catalytic domains [28].
Mutational analysis suggests that both domains are required for its
biochemical function [31]. LARGE is ubiquitously expressed and
is the only member of this group of proteins (together with
LARGE2) whose overexpression induces hyperglycosylation of a-
DG as judged by increased immunoreactivity to antibodies IIH6
and VIA41 both of which are known to recognise carbohydrate
epitopes [29,31]. Increased IIH6 immunoreactivity is accompa-
nied by an increase in laminin binding capacity, consistent with
the IIH6 epitope constituting a functional laminin binding glycan
[42]. Forced expression of LARGE is also capable of inducing the
synthesis of the IIH6 antigen in primary cell cultures derived from
patients with dystroglycanopathies [30]. More recently, acute
intramuscular adenoviral gene transfer of LARGE in fukutin and
POMGnT1 deficient mice has provided further proof that in vivo
forced overexpression restores a-DG glycosylation and ligand
binding [32]. Although originally it was suggested that LARGE
could exert its action via the modification of N-glycans [43] rather
than on O-mannosyl residues, recent observations indicate that this
protein is involved in the phosporylation of mannosyl residues on
a-DG [25]. Overall these data suggest that LARGE overexpres-
sion may be of therapeutic benefit to patients affected by a
dystroglycanopathy, irrespective of the primary gene defect.
Mutations in LARGE are exceptionally rare, with only a handful
of patients with proven mutations being identified since the
original description of MDC1D in 2003 [10]. This has led to the
suggestion that the administration of pharmacologically active
small molecules, capable of upregulating LARGE, or LARGE2
which however is essentially not expressed in muscle, or both,
could be an interesting therapeutic strategy for a broad range of
dystroglycanopathy patients [30,31,34].
In order to explore the efficacy and long term safety of LARGE
over-expression in vivo, we generated 4 independent LARGE
overexpressing transgenic mouse lines. As LARGE has previously
been reported to be expressed in a wide range of adult tissues, with
high levels in brain, heart, skeletal muscle, we wanted to
demonstrate if its generalised overexpression was capable of
inducing a-DG hyperglycosylation in these tissues and whether
this was associated with any detrimental effects. The LARGE
transgene was therefore put under control of a modified b-actin
promoter, previously shown to drive robust ubiquitous expression
in all tissues [44–46]. Interestingly whilst the expression of
LARGE was noted in several tissues, the hyperglycosylation of
a-DG was only observed in skeletal and cardiac muscles. In
skeletal muscle all fibres expressed the LARGE transgene. Since
LARGE is localised to a discrete subcellular region, most likely the
Golgi apparatus [31], expression in transverse sections was patchy.
However, longitudinal sections confirmed transgene expression in
virtually all fibres and increased IIH6 immunoreactivity also in all
fibres. As hyperglycosylation of a-DG could have affected its
interaction with its extracellular matrix ligands we studied the
skeletal muscle histology of young and aged mice (8 months).
Histologically the young and old LARGE transgenic muscles were
indistinguishable from littermate controls, including the dia-
phragm, a muscle particularly prone to pathological changes
because of the very frequent mechanical load. Immunohistochem-
ical studies of laminin a2 and b-DG were also identical to muscle
from control littermates. As abnormal dystroglycan glycosylation
has been shown to affect neuromuscular junctions (NMJ) [47,48]
we hypothesised that hyperglycosylation of a-DG may affect the
expression of two unique NMJ glycoforms of a-DG recognised by
the two cytotoxic T antigens (CT1 and CT2). However we could
demonstrate no morphological abnormality of NMJs and the
expression of CT1 and CT2 was unchanged in transgenic mice.
Detailed muscle physiological studies identified loss of force in
response to eccentric exercise in the older mice. As this
physiological deficit was absent in the younger mice, this suggests
that it developed over time. The reason for this deficit is not clear.
However basal lamina deposition and maintenance is a complex
phenomenon, following the initial deposition of laminin and its
transition from a monomeric to a polymerized state following
interaction with cellular receptors such as dystroglycan and
alpha7beta1D integrin [49]. We can therefore hypothesise that
the hyperglycosylation of a-DG alters some aspects of basement
membrane turnover. Interestingly, a defect of glycosylated
dystroglycan as present in the Large(myd) mice is also associated
with reduced sarcolemmal integrity and damage induced by
eccentric exercise, further indicating the role of the dystroglycan-
linked basal lamina to the maintenance of sarcolemmal integrity
and protection of muscles from damage [50]. The lack of obvious
muscle pathology in the limb muscles and the diaphragm of old
mice nevertheless suggests that this is a subtle, and subclinical
defect.
LARGE transgene expression and a-DG hyperglycosylation
was also detected in cardiac muscle in all transgenic lines; however
in this organ there was a patchy expression of the transgene. We
do not know why only a subset of cardiomyocytes expressed the
transgene. To our knowledge this is a unique observation using the
pCAGGs vector, which has been used extensively in the
generation of transgenic mouse lines. Increased IIH6 immunore-
activity was restricted to regions of transgene expression.
Histologically, there was no difference between the transgenic
hearts compared to the non transgenic littermates.
When the pattern of LARGE transgene expression in the brain
was studied, we demonstrated that its expression was restricted to a
discrete number of cell types, including the hippocampus,
cerebellum and cortex and associated primarily with neuronal
cells. Unlike skeletal and cardiac muscles, however, transgene
expression was not apparently associated with significant a-DG
hyperglycosylation in any of the neurons. Western blotting analysis
of total brain lysates confirmed what was seen at the cellular level
namely that there was no a-DG hyperglycosylation.
The failure to achieve a-DG hyperglycosylation in transgenic
mouse brains may be due to insufficient transgene expression in
this tissue, although the promoter used has been previously shown
to be ubiquitously expressed. However we were able to
(n=6) and their non-transgenic littermates (n=4). (C) In contrast in 8 month old mice the number of eccentric contractions had significant effects on
the force drop (p=0.04 and ,0.001, respectively). There was no difference between LARGE transgenic mice (n=4) and their negative littermates
(n=4) when the number of eccentric contractions was less than 5, but there were significant differences between LARGE transgenic and wild-type
mice at 5, 6, 7 and 8 eccentric contractions (p=0.01, 0.0007, ,0.0001 and ,0.0001 respectively). All values presented are mean and standard error of
the mean (S.E.M).
doi:10.1371/journal.pone.0014434.g005
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Large expression; we therefore hypothesise that the amount of
LARGE transgene expression required to bring about a fold
increase in overall protein levels is much greater in brain than in
skeletal and cardiac muscles, which have considerably lower levels
of endogenous Large expression. While this suggests that it might
be more difficult to achieve hyperglycosylation in this tissue, it
should be considered that the most severe structural brain defects
seen in patients are developmental in origin and would not be
helped by postnatal restoration of a-DG function [51].
The lack of any perturbation in the expression profiles of
glycosyltransferases involved in DG glycosylation strengthens the
argument that LARGE induced hyperglycosylation recruits a
different set of enzymes and functions by activating an alternative
enzymatic pathway. Our results further suggest that a strategy
aimed at inducing hyperglycosylation of a-DG has no obvious
detrimental effects on muscle histology, at least in mice. While we
found a physiological impairment of old transgenic mice, this was
not accompanied by any pathological changes. Although this
suggests that the effect of hyperglycosylation strategies might need
to be evaluated carefully, it is important to acknowledge both that
the deficit was only subclinical and also that the transgenic
overexpression of LARGE in a normal muscle differs radically
from the situation in a muscle depleted of glycosylated a-DG
epitopes, such as in the dystroglycanopathies, where the absence of
a proper a-DG-laminin interaction plays a major pathogenic role.
It will nevertheless be important to demonstrate safety and efficacy
of this strategy on the muscle physiology phenotype of models
deficient in enzymes involved in the glycosylation of a-DG. These
results are also encouraging in view of the recent findings
indicating that only modest restoration of IIH6 and laminin
binding might be associated with a beneficial effect in muscle of a
Figure 6. Immunocytochemistry of LARGE transgenic mouse cardiac muscle. Serial cryosections of control (A,C,G,I and K) and transgenic
(line 68) (B,D–F, H, J and L) cardiac muscle (aged 2 months) stained with: haematoxylin and eosin (A–B), anti-V5 (C–E), a-DG (IIH6) (F–H), b-
dystroglycan (I–J) and laminin a2 (K–L). E and F are images of whole heart sections of D and H. These images clearly show that the LARGE transgene is
only expressed in a proportion of cardiomyocytes and that a-DG hyperglycosylation is confined to those cardiomyocytes positive for V5. No
difference was seen in the level of b-DG (I and J) and laminin-a2 (K and L) immunoreactivity in LARGE transgenic cardiac muscle relative to control
littermates. (Scale bar 50 mm).
doi:10.1371/journal.pone.0014434.g006
Figure 7. Immunocytochemistry of LARGE transgenic mouse brain. Cryosections of brains from LARGE transgenic (line 68) (A–C,G–L) and
wild type littermates (D–F) at 2 months of age. Sections were stained using antibodies: V5 (A,D,G,J); a-DG (IIH6) (B,E and H); GM130, a Golgi marker,
(K). Nuclei were stained with Hoechst 33258 (blue). C,F,I and L are merged images. Cells expressing different levels of V5 (LARGE) were seen in the
hippocampal pyramidal layer (A) while IIH6 a-DG stained only vessels (B). In the cerebellum, immunolabelling of V5 was detected in Purkinje cells (G,
white arrow). In these cells IIH6 a-DG was seen around the cell soma (H, arrow), in a similar level to wild type Purkinje cells (E, arrow). Colocalisation of
V5 and GM130 in neuronal cells of the cerebral cortex (L) shows that the transgene was localised to the Golgi.
doi:10.1371/journal.pone.0014434.g007
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affected by dystroglycanopathies, especially LGMD2I, are rela-
tively mild variants with no evidence of brain involvement, a
modest increase in a-DG hyperglycosylation such as could be
achieved with pharmacological intervention, might be expected to
produce a significant benefit in the function of skeletal and cardiac
muscle, primary targets for the condition [52,53].
Materials and Methods
Ethics Statement
All animal experiments were conducted under a Project Licence
(PPL 70/6797) as mandated by the Animals (Scientific Procedures)
Act (1986). The study conformed to the guidelines published by
the Home Office in the UK and the local guidelines at Imperial
College London.
Generation of transgene cassette
Human LARGE cDNA derived from total brain RNA was
cloned into the pcDNA 3.1/V5-His TOPO expression vector as
reported previously [31]. This directs the synthesis of a fusion
protein with the V5 epitope at the C terminal end. The entire
LARGE/V5 DNA sequence was subsequently amplified by PCR
using primers to the T7 and BGH reverse priming sites and blunt
ligated into a BalI linearised pCAGGS vector (nt1865). The
transgene expression vector was then digested with HindIII and
SalI to release a 4kb cassette for micro injection. After purification
the transgene was injected into the pronuclei of single cell fertilised
eggs from C57BL106CBA/Ca hybrid mice which were then
placed in pseudo pregnant CD-1 foster mothers. Three weeks after
birth DNA was extracted from small ear biopsies and integration
of the transgene cassette was identified by PCR using a primer
located within the LARGE coding sequence at nt361(LGS;
CTGCCCAATGCTAAGATG) and one in the flanking portion
of the cassette (T7 primer). Founder transgenics were then bred
with C57BL106CBA/Ca hybrid mice to establish independent
transgenic lines for subsequent analysis.
Immunocytochemistry and histology
Samples for histology and immunocytochemistry were collected
from transgenic and non transgenic littermates following cervical
dislocation and frozen on cork blocks with Cryoembed in
isopentane cooled in liquid nitrogen before storage at 280uC.
Cryostat sections (8 mm) were air-dried for 30 min at room
temperature. Where mouse monoclonal antibodies were used the
sections were pretreated with the M.O.M.
TM Kit (Vector Labs)
according the manufacturer’s instructions, to reduce background
or non-specific staining of mouse tissues. Sections were incubated
with an anti-goat V5 FITC conjugated antibody (Bethyl
laboratotries, USA) for 1 hour. For double staining, the sections
were incubated with the following antibodies: a-DG IIH6 (a kind
gift from KP Campbell), NeuN (Millipore,UK, MAB377), Ctip2
(Abcam, UK), GM130 (BD Biosciences, USA), laminin a-2 (Alexis
Biochemicals, Enzo Life Sciences Ltd (UK)), b-DG (Vector Labs,
UK). After washing, the sections were incubated with an
appropriate biotinylated secondary antibody for 30min followed
by incubation with streptavidin conjugated to Alexa 594
(Molecular Probes, Invitrogen,USA) for 20 minutes. All the
Figure 8. Tissue Expression of endogenous Large and transgenic LARGE. Real time qPCR analysis of endogenous Large and LARGE
transgene expression is various tissues from transgenic line 115. All levels are relative to those seen in skeletal muscle (=1) and have been normalised
using 18sRNA levels. No differences in levels of endogenous Large were seen between control littermates and transgenic mice. Error bars are
standard errors based on 3 separate experiments.
doi:10.1371/journal.pone.0014434.g008
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with Hoechst 33258 (Invitrogen, USA). All dilutions and washings
were made in phosphate buffered saline. Sections were mounted in
aqueous mountant and viewed with epifluorescence using a Leica
Diaphot microscope and digitally captured using Metamorph
(Universal Imaging Inc). Control sections were used to set the
exposure time and scale settings for the digital capturing system.
Haematoxylin and eosin (H&E) and nicotinamide adenine
dinucleotide dehydrogenase-tetrazolium reductase (NADH-TR)
stainings were carried out in order to assess cell morphology,
inflammatory infiltrate and fibre type.
Western blotting and laminin overlay assays
Cell proteins were extracted in sample buffer consisting of
75 mM Tris–HCl, 1% SDS, 2-mercaptoethanol, plus a cocktail of
protease inhibitors (Roche). 30ug of soluble proteins were resolved
using a NuPage Pre-cast gel (4–12% Bis–Tris; Invitrogen, USA)
and then transferred electrophoretically to nitrocellulose mem-
brane (Hybond-ECL, GE Healthcare, UK. Nitrocellulose strips
were blocked in 3% BSA (IgG and protease-free, Jackson
Laboratories, USA) in Tris-buffered saline buffer, and then
probed with the primary antibodies: anti mouse a-DG IIH6
(Millipore UK,cat,05-593) anti-mouse b-DG (Vector Labs,UK),
anti-mouse V5 (Invitrogen, USA) at room temperature for 1 hour.
After washing they were incubated with the appropriate
biotinylated secondary antibody: anti IgM (Dako,Denmark), anti
mouse IgG (GE Healthcare, UK) followed by a HRP-streptavidin
(Dako, Denmark). All the incubations were for 1 hour at room
temperature. After washing, membranes were visualized using
chemiluminescence (ECL+Plus,GE Healthcare, UK). For the
laminin overlay assay, nitrocellulose membranes were blocked
for 1 hour in laminin binding buffer (LBB: 10 mM triethanol-
amine, 140 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, pH 7.6)
containing 5% non-fat dry milk followed by incubation of mouse
Engelbreth-Holm-Swarm laminin (Invitrogen,USA) overnight at
4uC in LBB. Membranes were washed and incubated with anti
rabbit laminin (Sigma, USA) followed by HRP-anti rabbit IgG
(Jackson ImmunoResearch, USA). Blots were visualized using
chemiluminescence (ECL+Plus, GE Healthcare,UK).
Immunocytochemistry for CT antigens
10 mm transverse sections of the Gastrocnemius were blocked
with 3% BSA (Sigma) in PBS for 1h. The CT1 and CT2
antibodies (a kind gift from Paul T. Martin) were diluted in 3%
BSA/PBS, and the slides incubated overnight at 4uC. The
following day, slides were incubated for 1hour with a biotinylated
anti-mouse IgM (Molecular Probes, Invitrogen,USA) followed by
incubation with streptavidin Alexa 594 (Molecular Probes,
Invitrogen, USA). NMJs were visualised using alpha-bungarotoxin
conjugated with Alexa 488 (Molecular Probes, Invitrogen, USA)
and the nuclei stained with Hoechst 33342 (Molecular Probes,
Invitrogen, USA). Sections were mounted in aqueous mountant
and viewed with epifluorescent using a Nikon Eclipse 1000, and
digitally captured with Imaging Software Pro Plus. Appropriate
controls were performed with secondary antibodies only.
Neuromuscular Junction Morphology
Diaphragms from normal and transgenic mice were dissected,
fixed in 4% paraformaldehyde and stained en bloc. They were first
incubated in PBS plus Triton 0.5% for 10 min followed by
incubation with of a-bungarotoxin Alexa 488 (Molecular Probes,
Invitrogen, USA) for 10 minutes. Nuclei were stained with
Hoechst 33342 and sections were then mounted in aqueous
mountant. Images were captured and the area of muscle fibre
covered by the NMJ measured using a Leica DMR epifluores-
cence microscope interfaced with Metamorph software. Only
those neuromuscular junction images where the full area was
visible were analysed.
RT-PCR analysis
Tissues of interest were dissected out and homogenized with
liquid nitrogen using a mortar and pestle and the lysate passed
through a QiaShredder (Qiagen, USA). The RNA was isolated
from the homogenized tissue using an RNeasy kit (Qiagen,USA)
and eluted in 30 ml. About 1 mg of RNA was reverse transcribed
with Superscript III for qRT-PCR kit (Invitrogen,USA). qRT-
PCR was performed on a 7500 FAST Real-Time PCR system
(Applied Biosystems,USA) using TaqMan Universal PCR Mas-
termix and TaqMan gene expression assays (Applied Biosystems,
USA). Expression levels of transgenic LARGE and endogenous
Large were normalised using 18sRNA levels. All reactions were
performed in triplicate.
In situ Muscle Function and Lengthening Contraction
Mice were anaesthetised with an intra-peritoneal injection of
Hypnorm/Hypnovel/water (1:1:2 by vol.) at a dosage of 10 ml/kg
(Hypnorm, VetPharma,UK and Hypnovel,Roche,UK). The mice
were carefully monitored throughout the experiment and
additional doses of anaesthetic were administered to ensure that
there was no reflex response to toe pinch. Under deep anaesthesia
the distal tendon of the tibialis anterior (TA) muscle was dissected
from surrounding tissue and the tendon tied with 4.0 braided
surgical silk. The sciatic nerve was exposed and all its branches cut
except for the common peroneal nerve (CPN), which innervates
the TA muscle. The mouse was placed on a thermopad (Harvard
Apparatus) to maintain body temperature at 37uC. The foot was
secured to a platform and the ankle and knee immobilized using
stainless steel pins. The TA tendon was attached to the lever arm
of a 305B dual-mode servomotor transducer (Aurora Scientific
Inc., Ontario, Canada) via a custom made steel s-hook. TA muscle
contractions were elicited by stimulating the distal part of CPN via
bipolar platinum electrodes, using supramaximal square-wave
pulses of 0.02 ms (701A stimulator; Aurora Scientific Inc). Data
acquisition and control of the servomotors were conducted using a
Lab-View based DMC program (Dynamic muscle control and
Data Acquisition; Aurora Scientific, Inc.). Optimal muscle length
(Lo) was determined by incrementally stretching the muscle using
micromanipulators until the maximum isometric twitch force was
achieved. The peak twitch force (Pt), time to peak twitch force
(TPT), half relaxation time of the twitch (HRT) and the specific
twitch force (sPt, Pt normalised for cros sectional area) was
recorded for each mouse. The maximum isometric tetanic force
(Po) was determined from the plateau of the force-frequency
relationship following a series of stimulations at 10, 30, 40, 50, 80,
100, 120, 150, and 180 Hz. A one minute rest period was allowed
between each tetanic contraction. Muscle length was measured
using digital calipers based on well defined anatomical landmarks
near the knee and the ankle. The specific force (N/cm
2) was
calculated by dividing Po by TA muscle cross-sectional area (CSA).
Overall CSA was estimated using the following formula: muscle
weight (g)/[Lo (cm)61.06 (g/cm
3).
After establishing the force-frequency relationship, the suscep-
tibility of TA muscles to eccentric contraction-induced injury was
assessed. This consisted of stimulating the muscle at 180 Hz (the
frequency that usually resulted in Po) for 700 ms. After 500 ms of
stimulation the muscle was lengthened by 15% of Lo at a velocity
of 0.75 Lo s/1. At the end of stimulation the muscle was returned
to Lo at a rate of 20.75 Lo s/1. The stimulation-stretch cycle was
a-DG in Transgenic LARGE Mice
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between each cycle limited the potential for developing muscle
fatigue. Maximum isometric force was measured after each
eccentric contraction and expressed as a percentage of the initial
maximum isometric force. At the end of the experiment the
muscles were excised and weighed.
Statistics: Mixed effect models were employed to study the effect
of genotype, number of eccentric contractions and their
interaction on outcome variables, and first-order autoregressive
structure was adopted to account for the correlation structure
between repeated measures from the same mouse. These analyses
were carried out using the MIXED procedure in SAS version 9.1
for PC (Copyright, SAS Institute Inc. Cary, NC, USA).
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